K36’s program is the first to study the promise of targeting the methyltransferase nuclear receptor SET domain-containing 2 (NSD2, also known as MMSET) for the treatment of hematologic and solid …

Now Enrolling: K36-MMSET-001 Clinical Trial for Relapsed/Refractory Multiple Myeloma We are actively enrolling patients in the US, Canada, France & Spain in our ongoing Phase 1 clinical trial evaluating …

Aug 6, 2025 · K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical …

At K36, we are developing KTX-1001, a potent and selective NSD2 inhibitor designed to reduce H3K36me2 levels and reverse oncogenic transcriptional programs in NSD2-dysregulated myeloma.

Disciplined. Resourceful. Intellectually Curious. United in our focus to improve the lives of cancer patients with unmet medical needs.

At K36 Therapeutics, we’re pioneering the development of selective, potent NSD2 inhibitors to treat cancers driven by epigenetic dysregulation - starting with multiple myeloma and prostate cancer.

Shinta Cheng, MD, PhD, brings more than two decades of experience in oncology and hematology drug development to his role as Chief Medical Officer at K36 Therapeutics.

Aug 7, 2025 · K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical …

Soo brings over 25 years of experience in the biopharmaceutical, healthcare and clinical research industry to K36. She started her career in clinical research in the academic healthcare of GWU, NYU, …

Our Leadership Terry Connolly, PhD President, Chief Executive Officer, K36 Board Member Shinta Cheng, MD, PhD Chief Medical Officer Soo Bang, MHSA